TY - JOUR
T1 - Dopaminergic Retinal Cell Loss and Visual Dysfunction in Parkinson Disease
AU - Ortuño-Lizarán, Isabel
AU - Sánchez-Sáez, Xavier
AU - Lax, Pedro
AU - Serrano, Geidy E.
AU - Beach, Thomas G.
AU - Adler, Charles H.
AU - Cuenca, Nicolás
N1 - Funding Information:
This work was supported by the Michael J. Fox Foundation for Parkinson's Research. I.O.‐L. and X.S.‐S. acknowledge financial support from the Ministry of Education, Spain (FPU 14/03166; FPU 16/04114). N.C. acknowledges financial support from the Ministry of Economy and Competitiveness, Spain (MINECO‐FEDER‐BFU2015‐67139‐R), Carlos III Institute of Health (RETICS‐FEDER RD16/0008/0016), Retina Asturias Association, and Generalitat Valenciana‐European Regional Development Fund (IDIFEDER/2017/064). The Brain and Body Donation Program has been supported by the NIH National Institute of Neurological Disorders and Stroke (U24 NS072026), the NIH National Institute on Aging (P30 AG19610), the Arizona Department of Health Services, the Arizona Biomedical Research Commission, and the Michael J. Fox Foundation for Parkinson's Research.
Funding Information:
This work was supported by the Michael J. Fox Foundation for Parkinson's Research. I.O.-L. and X.S.-S. acknowledge financial support from the Ministry of Education, Spain (FPU 14/03166; FPU 16/04114). N.C. acknowledges financial support from the Ministry of Economy and Competitiveness, Spain (MINECO-FEDER-BFU2015-67139-R), Carlos III Institute of Health (RETICS-FEDER RD16/0008/0016), Retina Asturias Association, and Generalitat Valenciana-European Regional Development Fund (IDIFEDER/2017/064). The Brain and Body Donation Program has been supported by the NIH National Institute of Neurological Disorders and Stroke (U24 NS072026), the NIH National Institute on Aging (P30 AG19610), the Arizona Department of Health Services, the Arizona Biomedical Research Commission, and the Michael J. Fox Foundation for Parkinson's Research.
Publisher Copyright:
© 2020 American Neurological Association
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Objective: Considering the demonstrated implication of the retina in Parkinson disease (PD) pathology and the importance of dopaminergic cells in this tissue, we aimed to analyze the state of the dopaminergic amacrine cells and some of their main postsynaptic neurons in the retina of PD. Methods: Using immunohistochemistry and confocal microscopy, we evaluated morphology, number, and synaptic connections of dopaminergic cells and their postsynaptic cells, AII amacrine and melanopsin-containing retinal ganglion cells, in control and PD eyes from human donors. Results: In PD, dopaminergic amacrine cell number was reduced between 58% and 26% in different retinal regions, involving a decline in the number of synaptic contacts with AII amacrine cells (by 60%) and melanopsin cells (by 35%). Despite losing their main synaptic input, AII cells were not reduced in number, but they showed cellular alterations compromising their adequate function: (1) a loss of mitochondria inside their lobular appendages, which may indicate an energetic failure; and (2) a loss of connexin 36, suggesting alterations in the AII coupling and in visual signal transmission from the rod pathway. Interpretation: The dopaminergic system impairment and the affection of the rod pathway through the AII cells may explain and be partially responsible for the reduced contrast sensitivity or electroretinographic response described in PD. Also, dopamine reduction and the loss of synaptic contacts with melanopsin cells may contribute to the melanopsin retinal ganglion cell loss previously described and to the disturbances in circadian rhythm and sleep reported in PD patients. These data support the idea that the retina reproduces brain neurodegeneration and is highly involved in PD pathology. ANN NEUROL 2020;88:893–906.
AB - Objective: Considering the demonstrated implication of the retina in Parkinson disease (PD) pathology and the importance of dopaminergic cells in this tissue, we aimed to analyze the state of the dopaminergic amacrine cells and some of their main postsynaptic neurons in the retina of PD. Methods: Using immunohistochemistry and confocal microscopy, we evaluated morphology, number, and synaptic connections of dopaminergic cells and their postsynaptic cells, AII amacrine and melanopsin-containing retinal ganglion cells, in control and PD eyes from human donors. Results: In PD, dopaminergic amacrine cell number was reduced between 58% and 26% in different retinal regions, involving a decline in the number of synaptic contacts with AII amacrine cells (by 60%) and melanopsin cells (by 35%). Despite losing their main synaptic input, AII cells were not reduced in number, but they showed cellular alterations compromising their adequate function: (1) a loss of mitochondria inside their lobular appendages, which may indicate an energetic failure; and (2) a loss of connexin 36, suggesting alterations in the AII coupling and in visual signal transmission from the rod pathway. Interpretation: The dopaminergic system impairment and the affection of the rod pathway through the AII cells may explain and be partially responsible for the reduced contrast sensitivity or electroretinographic response described in PD. Also, dopamine reduction and the loss of synaptic contacts with melanopsin cells may contribute to the melanopsin retinal ganglion cell loss previously described and to the disturbances in circadian rhythm and sleep reported in PD patients. These data support the idea that the retina reproduces brain neurodegeneration and is highly involved in PD pathology. ANN NEUROL 2020;88:893–906.
UR - http://www.scopus.com/inward/record.url?scp=85091047401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091047401&partnerID=8YFLogxK
U2 - 10.1002/ana.25897
DO - 10.1002/ana.25897
M3 - Article
C2 - 32881029
AN - SCOPUS:85091047401
SN - 0364-5134
VL - 88
SP - 893
EP - 906
JO - Annals of neurology
JF - Annals of neurology
IS - 5
ER -